These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19704058)

  • 1. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
    Lilenbaum R; Wang X; Gu L; Kirshner J; Lerro K; Vokes E
    J Clin Oncol; 2009 Sep; 27(27):4487-91. PubMed ID: 19704058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
    Lara PN; Longmate J; Reckamp K; Gitlitz B; Argiris A; Ramalingam S; Belani CP; Mack PC; Lau DH; Koczywas M; Wright JJ; Shepherd FA; Leighl N; Gandara DR
    Clin Lung Cancer; 2011 Jan; 12(1):33-7. PubMed ID: 21273177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
    Fanucchi MP; Fossella FV; Belt R; Natale R; Fidias P; Carbone DP; Govindan R; Raez LE; Robert F; Ribeiro M; Akerley W; Kelly K; Limentani SA; Crawford J; Reimers HJ; Axelrod R; Kashala O; Sheng S; Schiller JH
    J Clin Oncol; 2006 Nov; 24(31):5025-33. PubMed ID: 17075122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
    Lara PN; Koczywas M; Quinn DI; Lenz HJ; Davies AM; Lau DH; Gumerlock PH; Longmate J; Doroshow JH; Schenkein D; Kashala O; Gandara DR
    J Thorac Oncol; 2006 Feb; 1(2):126-34. PubMed ID: 17409841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.
    Spigel DR; Greco FA; Thompson DS; Webb C; Rubinsak J; Inhorn RC; Reeves J; Vazquez ER; Lane CM; Burris HA; Hainsworth JD
    Clin Lung Cancer; 2010 May; 11(3):198-203. PubMed ID: 20439197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
    Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
    Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
    Piperdi B; Walsh WV; Bradley K; Zhou Z; Bathini V; Hanrahan-Boshes M; Hutchinson L; Perez-Soler R
    J Thorac Oncol; 2012 Jun; 7(6):1032-40. PubMed ID: 22534815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).
    Socinski MA; Saleh MN; Trent DF; Dobbs TW; Zehngebot LM; Levine MA; Bordoni R; Stella PJ
    Ann Oncol; 2009 Jun; 20(6):1068-73. PubMed ID: 19188136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
    Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
    Belani CP; Schreeder MT; Steis RG; Guidice RA; Marsland TA; Butler EH; Ramalingam SS
    Cancer; 2008 Nov; 113(9):2512-7. PubMed ID: 18816622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
    Rosell R; Robinet G; Szczesna A; Ramlau R; Constenla M; Mennecier BC; Pfeifer W; O'Byrne KJ; Welte T; Kolb R; Pirker R; Chemaissani A; Perol M; Ranson MR; Ellis PA; Pilz K; Reck M
    Ann Oncol; 2008 Feb; 19(2):362-9. PubMed ID: 17947225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
    Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
    J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
    Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
    Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
    Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
    Novello S; Falcone A; Crinò L; Rinaldi M; Nardi M; De Marinis F; Tonato M; Tibaldi C; Tinazzi A; Russo F; Grassivaro N; Scagliotti GV
    Lung Cancer; 2009 Dec; 66(3):327-32. PubMed ID: 19329221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.
    Butts CA; Bodkin D; Middleman EL; Englund CW; Ellison D; Alam Y; Kreisman H; Graze P; Maher J; Ross HJ; Ellis PM; McNulty W; Kaplan E; Pautret V; Weber MR; Shepherd FA
    J Clin Oncol; 2007 Dec; 25(36):5777-84. PubMed ID: 18089875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
    Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
    J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.
    Kim ES; Mauer AM; William WN; Tran HT; Liu D; Lee JJ; Windt P; Hong WK; Vokes EE; Herbst RS
    Cancer; 2009 Apr; 115(8):1713-22. PubMed ID: 19208430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.